768P Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)

P Pautier,J-S Fresnel,B You,F Bazan,C Lebreton,A Leary,D Chaltiel

doi:10.1016/j.annonc.2023.09.1947

768P Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)

P Pautier, J-S Fresnel + Show 5 more

Open Access

https://doi.org/10.1016/j.annonc.2023.09.1947

Copy DOI

Journal: Annals of Oncology

Publication Date: Oct 1, 2023

Affiliation: Institut Gustave Roussy, Institut de Cancérologie de l'Ouest, Institut Bergonié

#Relapsed Platinum Sensitive Ovarian Cancer #PARP Inhibitor In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

768P Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)

Full Text